410-bp cmGAD67 Promoter Suppresses Seizures in Mice by Driving Gene Expression in Inhibitory Neurons
Background: Cell selectivity in a compact vector
Researchers at Gunma University in Japan developed cmGAD67, a 410-base-pair (bp) promoter that drives gene expression in inhibitory neurons. When used to express glutamate decarboxylase 65 (GAD65), this regulatory sequence improved abnormal brain-wave activity and some seizure-related measures in mouse seizure models. The study did not test treatment efficacy in people with epilepsy, and the findings were published in Molecular Therapy.
When the balance between excitation and inhibition in the brain shifts toward excitation, abnormal circuit activity associated with seizures can emerge. Gene delivery aimed at strengthening inhibitory-neuron function is one approach to regulating this balance. However, adeno-associated virus (AAV) vectors have a packaging capacity of about 4.7 kb, so space must be reserved for both the promoter that regulates gene expression and the therapeutic gene.
The researchers’ previously developed 2,542-bp promoter, mGAD65(delE1), could be packaged in AAV but occupied more than half of its packaging capacity and had relatively weak expression activity. The goal of the current study was to identify a shorter sequence with inhibitory-neuron selectivity and strong expression activity.
Key findings: Expression performance and model-specific effects
The researchers progressively shortened the regulatory region of the mouse Gad1 gene and identified cmGAD67, composed of a core promoter and Rii, an enhancer that supports expression. Three weeks after intravenous administration of an AAV-PHP.eB vector, they analyzed the motor cortex. Relative green fluorescent protein (GFP) mRNA expression was 1.8±0.1 in the cmGAD67 group, compared with 1.0±0.2 in the group using the earlier promoter. Each group included six mice, and values are the mean±standard error of the mean. This was a comparison of reporter-gene expression; it should not be interpreted as a 1.8-fold therapeutic effect.
Expression was concentrated in inhibitory neurons, with a preference for parvalbumin (PV)-positive interneurons. It was not restricted to PV-positive cells. In a separate experiment using GFP and an inhibitory designer receptor, direct injection into the hippocampus produced lower inhibitory-neuron selectivity than intravenous administration, showing that the delivery route also affected selectivity.
Therapeutic potential was assessed using AAV-GAD65, which expresses GAD65 under the control of cmGAD67. In a model involving repeated administration of pentylenetetrazol (PTZ) at 30 mg/kg, the vector was given intravenously two days after the final PTZ dose. Electroencephalograms were compared on days 1 and 22 after the final PTZ dose. On day 22, delta-band power was lower in the AAV-GAD65 group than in the PTZ-only and GFP-vector control groups. However, seizure-like event counts alone did not show a significant reduction; a combined analysis of event counts and delta power showed a shift toward the normal group.
In a severe model using PTZ at 35 mg/kg, the study reported reduced seizure progression and improved survival. This was a preventive design: the vector was administered three weeks before PTZ treatment began. In a separate local model in which excitatory neurons were activated chemogenetically, seizure behavior and electrophysiological measures decreased. Biochemical analyses of the cortex and hippocampus also showed increased levels of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, supporting the interpretation that inhibitory neurotransmission was strengthened.
Implications and outlook: Potential as a preclinical delivery tool
The findings suggest that a compact promoter can drive GAD65 expression in inhibitory neurons and may reduce circuit hyperexcitability across several mouse models. Anxiety-like behavior in the PTZ model also improved, while no abnormalities were observed in the motor and circadian behaviors assessed. These observations do not establish long-term safety or efficacy for treating anxiety disorders in people.
The study relied mainly on induced seizure models. These do not fully reproduce drug-resistant epilepsy in people or chronic and varied disease states, so the approach needs testing in chronic epilepsy models and in larger brains. Further work should assess long-term safety, off-target expression, distribution in peripheral tissues, and selectivity by delivery route. The researchers’ interpretation that GAD65 may act more strongly during hyperexcitability also does not demonstrate an automatic control mechanism that switches on only during pathological episodes.
The study design and results are available in the original paper.
Epilepsy arises from disruption of excitation-inhibition (E/I) balance, typically due to excessive excitatory activity. Despite available therapies, a substantial proportion of patients remain treatment resistant. Enhancing inhibitory neuron activity via gene therapy can restore E/I balance and may therefore provide a therapeutic strategy for treatment-resistant epilepsy. Here, we developed a compact 410-bp glutamic acid decarboxylase 67 promoter (cmGAD67) that enables strong, selective transgene expression in inhibitory neurons while preserving adeno-associated virus (AAV) packaging capacity. Systemic delivery of AAV vectors carrying cmGAD67 preferentially targeted parvalbumin interneurons and enabled efficient circuit modulation. To evaluate therapeutic potential, we expressed glutamic acid decarboxylase 65 (GAD65) under the control of cmGAD67 (AAV-GAD65). AAV-GAD65 suppressed abnormal delta oscillations, reduced seizure-like activity, normalized anxiety-like behavior, and improved survival in seizure models. Biochemical analyses confirmed increased GABA levels in the cortex and hippocampus, linking functional improvements to enhanced inhibitory neurotransmitter synthesis. Together, these findings establish the cmGAD67 promoter as a versatile platform for inhibitory neuron-targeted AAV gene delivery and identify AAV-GAD65 as a promising strategy for seizure control and disorders associated with E/I imbalance.
cmGAD67 reduces the space occupied by the expression-regulating sequence, leaving room within AAV’s limited packaging capacity for a therapeutic gene or additional regulatory elements. Researchers could use the promoter to express genes in inhibitory neurons to investigate their role in seizure circuits or compare candidates for further preclinical development.
According to the paper, the promoter plasmid is registered with Addgene and available for research use. The paper also reports a related patent application, so research availability does not guarantee commercial freedom to operate. Using it for therapeutic development would require validation of selectivity by delivery route, efficacy in chronic models, and long-term safety. There is not yet evidence to extrapolate the survival improvement observed in mice to prevention of death in patients.